Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study

BMC Nephrology

Volumn 18, Issue 1, 2017, Pages

  Peters, N O ^a   Jay, N ^a,b   Cridlig, J ^a   Rostoker, G ^c   Frimat, L ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

^b LORIA   (France)

^c Claude Galien Hospital of the Ramsay Générale de Santé   (France)

Author keywords

Anemia; Chronic kidney disease; Dialysis; Intravenous iron

Indexed keywords

ANTIANEMIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN; HEMODIALYSIS FLUID;

AGED; ANEMIA; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE SEVERITY; DRUG INFUSION; FEMALE; HEART FAILURE; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; IRON DEFICIENCY; IRON OVERLOAD; ISCHEMIC HEART DISEASE; MALE; MALIGNANT NEOPLASM; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SUPPLEMENTATION; TRANSFERRIN SATURATION; TRANSPLANTATION; TREATMENT DURATION; TREATMENT OUTCOME; CLINICAL TRIAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG MONITORING; INTRAVENOUS DRUG ADMINISTRATION; LONGITUDINAL STUDY; PILOT STUDY; PROCEDURES;

AGED; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; HEMODIALYSIS SOLUTIONS; HUMANS; INJECTIONS, INTRAVENOUS; IRON; LONGITUDINAL STUDIES; PILOT PROJECTS; RENAL DIALYSIS; TREATMENT OUTCOME;

EID: 85015952138     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/s12882-017-0513-x     Document Type: Article

References (49)

1. Jones M, Ibels L, Schenkel B, Zagari M. Impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis. Kidney Int. 2004;65:757-67.
2. Levin A. Anemia and left ventricular hypertrophy in chronic kidney disease populations: a review of the current state of knowledge. Kidney Int. 2002;80:S35-8.
3. Collins AJ, Li S, St Peter W, Ebben J, Roberts T, Ma JZ, Manning W. Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol. 2001;12:2465-73.
4. Brookhart MA, Schneeweiss S, Avorn J, Bradbury BD, Liu J, Winkelmayer WC. Comparative mortality risk of anemia management practices in incident hemodialysis patients. JAMA. 2010;303:857-64.
5. Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med. 1998;339:584-90.
6. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, Investigators CHOIR. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085-98.
7. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int. 2012;2:S279-335.
8. Locatelli F, Bárány P, Covic A, De Francisco A, Del Vecchio L, Goldsmith D, Hörl W, London G, Vanholder R, Van Biesen W, ERA-EDTA ERBP Advisory Board. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant. 2013;28:1346-59.
9. Kliger AS, Foley RN, Goldfarb DS, Goldstein SL, Johansen K, Singh A, Szczech L. KDOQI US commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis. 2013;62:849-59.
10. Moist LM, Troyanov S, White CT, Wazny LD, Wilson JA, McFarlane P, Harwood L, Sood MM, Soroka SD, Bass A, Manns BJ. Canadian Society of Nephrology commentary on the 2012 KDIGO Clinical Practice Guideline for Anemia in CKD. Am J Kidney Dis. 2013;62:860-73.
11. Tsubakihara Y, Nishi S, Akiba T, Hirakata H, Iseki K, Kubota M, Kuriyama S, Komatsu Y, Suzuki M, Nakai S, Hattori M, Babazono T, Hiramatsu M, Yamamoto H, Bessho M, Akizawa T. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease. Ther Apher Dial. 2010;14:240-75.
12. National Institute for Health and Care Excellence (Nice). Anaemia Management in Chronic Kidney Disease. London: NICE; 2015. Available from https://www.nice.org.uk/guidance/ng8/evidence/full-guideline-70545133. Accessed 17 Mar 2017.
13. Locatelli F, Nissenson AR, Barrett BJ, Walker RG, Wheeler DC, Eckardt KU, Lameire NH, Eknoyan G. Clinical practice guidelines for anemia in chronic kidney disease: problems and solutions. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int. 2008;74:1237-40.
14. Locatelli F, Covic A, Eckardt KU, Wiecek A, Vanholder R, ERA-EDTA ERBP Advisory Board. Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP). Nephrol Dial Transplant. 2009;24:348-54.
15. Madore F, White CT, Foley RN, Barrett BJ, Moist LM, Klarenbach SW, Culleton BF, Tonelli M, Manns BJ, Canadian Society of Nephrology. Clinical practice guidelines for assessment and management of iron deficiency. Kidney Int. 2008;110:S7-11.
16. Rottembourg J, Rostoker G. Use of Iron Therapy in Chronic Kidney Disease. Arch Clin Nephrol. 2016;1:12-4.
17. Charytan DM, Barton Pai A, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S. Considerations and Challenges in Defining Optimal Iron Utilization in Hemodialysis. J Am Soc Nephrol. 2015;26:1238-47.
18. Freburger JK, Ng LJ, Bradbury BD, Kshirsagar AV, Brookhart MA. Changing patterns of anemia management in US hemodialysis patients. Am J Med. 2012;125:906-14.
19. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM. Variation in intravenous iron use internationally and over time: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2013;28:2570-9.
20. Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Nolen JG, Roger SD, on behalf of the FIND-CKD Study Investigators. FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol Dial Transplant. 2014;29:2075-84.
21. Macdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Cushway T, Roger SD, FIND-CKD Study Investigators. The FIND-CKD study a randomized controlled trial of intravenous iron versus oral iron in non-dialysis chronic kidney disease patients: background and rationale. Nephrol Dial Transplant. 2014;29:843-50.
22. Coyne DW, Kapoian T, Suki W, Singh AK, Moran JE, Dahl NV, Rizkala AR, DRIVE Study Group. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients Response to IV Iron with Elevated Ferritin (DRIVE) Study. J Am Soc Nephrol. 2007;18:975-84.
23. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, Zazra JJ, Anandan JV, Gupta A. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11:530-8.
24. Mitka M. New findings challenge thinking about anemia, iron deficiency, and heart risk. JAMA. 2010;303:405-6.
25. Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Lüscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart RB, Pocock SJ, Poole-Wilson PA, Ponikowski P, FAIR-HF Trial Investigators. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med. 2009;361:2436-48.
26. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, Malenka DJ, Ozaki CK, Lavori PW. Reduction of iron stores and cardiovascular outcomes in patients with peripheral arterial disease: a randomized controlled trial. JAMA. 2007;297:603-10.
27. Bailie GR, Larkina M, Goodkin DA, Li Y, Pisoni RL, Bieber B, Mason N, Tong L, Locatelli F, Marshall MR, Inaba M, Robinson BM. Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality. Kidney Int. 2015;87:162-8.
28. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int. 2015;88:905-14.
29. Kuragano T, Matsumura O, Matsuda A, Hara T, Kiyomoto H, Murata T, Kitamura K, Fujimoto S, Hase H, Joki N, Fukatsu A, Inoue T, Itakura I, Nakanishi T. Association between hemoglobin variability, serum ferritin levels, and adverse events/mortality in maintenance hemodialysis patients. Kidney Int. 2014;86:845-54.
30. Brookhart MA, Freburger JK, Ellis AR, Wang L, Winkelmayer WC, Kshirsagar AV. Infection risk with bolus versus maintenance iron supplementation in hemodialysis patients. J Am Soc Nephrol. 2013;24:1151-8.
31. Afzali B, Goldsmith DJ. Long-term risks of increased use of intravenous iron. Lancet. 2007;370:482.
32. Sullivan JL. Long-term risks of increased use of intravenous iron. Lancet. 2007;370:481-2.
33. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y. Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study. Am J Med. 2012;125:991-9.
34. Rostoker G, Cohen Y. Magnetic Resonance Imaging Repercussions of Intravenous Iron Products Used for Iron-Deficiency Anemia and Dialysis-Associated Anemia. J Comput Assist Tomogr. 2014;38:843-4.
35. Wysowski D, Swartz L, Borders-Hemphill V, Goulding MR, Dormitzer C. Use of parenteral iron products and serious anaphylactic-type reactions. Am J Hematol. 2010;85:650-4.
36. Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, Patni S, Szebeni J, Weiss G. Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management. Haematologica. 2014;99:1671-6.
37. New recommendations to manage risk of allergic reactions with intravenous iron-containing medicines. Available on http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/IV_iron_31/WC500151308.pdf. Accessed 17 Mar 2017.
38. INSTRUCTION N°DGOS/PF2/R3/DGS/PP2/2014/32 du 24 janvier 2014 relative aux modalités d’utilisation des spécialités à base de fer injectable. Ministère des Affaires sociales et de la Santé. Available on http://circulaire.legifrance.gouv.fr/pdf/2014/01/cir_37878.pdf. Accessed 17 Mar 2017.
39. Rostoker G, Hummel A, Chantrel F, Ryckelynck JP. Therapy of anemia and iron deficiency in dialysis patients: an update. Nephrol Ther. 2014;10:221-7. French.
40. Rottembourg J, Rostoker G. Use of intravenous iron supplementation in chronic kidney disease: Interests, limits, and recommendations for a better practice. Nephrol Ther. 2015;11:531-42. French.
41. Del Vecchio L, Longhi S, Locatelli F. Safety concerns about intravenous iron therapy in patients with chronic kidney disease. Clin Kidney J. doi: 10.1093/ckj/sfv142First published online: January 6, 2016
42. Kalantar-Zadeh K, Kalantar-Zadeh K, Lee GH. The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease? Clin J Am Soc Nephrol. 2006;1:S9-18.
43. Rostoker G, Griuncelli M, Loridon C, Magna T, Machado G, Drahi G, et al. Reassessment of Iron Biomarkers for Prediction of Dialysis Iron Overload: An MRI Study. PLoS ONE. 2015;10:e0132006. doi:10.1371/journal.pone.0132006.
44. Qunibi WY, Martinez C, Smith M, Benjamin J, Mangione A, Roger SD. A randomized controlled trial comparing intravenous ferric carboxymaltose with oral iron for treatment of iron deficiency anaemia of non-dialysis-dependent chronic kidney disease patients. Nephrol Dial Transplant. 2011;26:1599-607.
45. Van Wyck DB, Roppolo M, Martinez CO, Mazey RM, McMurray S, United States Iron Sucrose (Venofer) Clinical Trials Group. A randomized, controlled trial comparing IV iron sucrose to oral iron in anemic patients with nondialysis-dependent CKD. Kidney Int. 2005;68:2846-56.
46. Rozen-Zvi B, Gafter-Gvili A, Paul M, Leibovici L, Shpilberg O, Gafter U. Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta-analysis. Am J Kidney Dis. 2008;52:897-906.
47. Rhee CM, Kalantar-Zadeh K. Is iron maintenance therapy better than load and hold? J Am Soc Nephrol. 2013;24:1028-31.
48. Rostoker G, Griuncelli M, Loridon C, Magna T, Janklewicz P, et al. Maximal standard dose of parenteral iron for hemodialysis patients: an MRI-based decision tree learning analysis. PLoS ONE. 2014;9: e115096. doi:10.1371/journal.pone.0115096.
49. Claudot F, Alla F, Fresson J, Calvez T, Coudane H, Bonaïti-Pellié C. Ethics and observational studies in medical research: various rules in a common framework. Int J Epidemiol. 2009;38:1104-8.